Bank of America
NKTR icon

Bank of America’s Nektar Therapeutics NKTR Stock Holding History

Bank of America’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,093
Closed -$171K – 8046
2013
Q3 		$171K Buy
+1,093
New +$202K ﹤0.01% 5581

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of America's NKTR Position: Q1 2026 in Review

Bank of America increased its Nektar Therapeutics (NKTR) stake by 126% in Q1 2026, buying an estimated $1.87M and bringing the position to 58,958 shares worth $4.24M. The position accounts for ﹤0.01% of the portfolio, ranked #3594.

Bank of America first reported a position in NKTR in Q2 2013 and has held it in 52 quarters since. The position peaked at $107M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Bank of America held 58,958 shares of Nektar Therapeutics worth $4.24M as of Q1 2026.
  • Bank of America bought 32,866 Nektar Therapeutics shares in Q1 2026, an estimated $1.87M.
  • Nektar Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3594 holding.
  • Bank of America first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Bank of America's Nektar Therapeutics position peaked at $107M in Q1 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.